Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway.
Level 5 - mechanism / opinion, no new human data
Animal model experiment without human clinical data
PubMed 41688761 · doi:10.1038/s41386-026-02361-x
What was done
Researchers evaluated the therapeutic effects of psilocybin microdosing on novel object recognition (NOR) memory in an Fmr1-Δ exon 8 rat model of Fragile X Syndrome. To determine the molecular mechanism, they tested whether the behavioral recovery was blocked by the 5-HT2A receptor antagonist volinanserin, the 5-HT1A receptor antagonist WAY-100635, or the TrkB receptor antagonist ANA-12. Mature BDNF (mBDNF), TrkB expression, and downstream AKT signaling were quantified in the prefrontal cortex.
What was found
Psilocybin microdosing rescued NOR memory deficits in the mutant rats. This rescue persisted under 5-HT2A or 5-HT1A receptor antagonism, but was completely abolished by the TrkB antagonist ANA-12. Molecular analysis showed that psilocybin normalized mBDNF, increased TrkB levels, and restored downstream AKT signaling in the prefrontal cortex. The abstract provided no specific numerical values, sample sizes, or dosage amounts.
Why it matters
These findings suggest that psilocybin-mediated cognitive improvements in this Fragile X Syndrome model occur via neurotrophic BDNF/TrkB-AKT signaling rather than canonical psychedelic 5-HT2A pathways, supporting the concept of non-hallucinogenic microdosing regimens for neurodevelopmental disorders.
Limits
The findings are restricted to an animal model and cannot directly establish clinical efficacy in humans. The abstract omits sample sizes, specific dosage regimens, quantitative effect sizes, and evaluation of other core Fragile X phenotypes.
Cited by
- supports Psilocybin lowers the activity of the brain's default mode network and activates brain-derived neurotrophic factor (BDNF) to increase neural connectivity and neurogenesis.